Listar MD - Artículos por autor "Alba-Conejo, Emilio"
Mostrando ítems 1-19 de 19
-
A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression
Ribelles, Nuria; López-Siles, J; Sánchez-Muñoz, Alfonso
; Sánchez, E; González, E; Sánchez, MJ; Carabantes, F; Sánchez- Rovira, P; Márquez, A; Dueñas, R; Sevilla, I; Alba-Conejo, Emilio[et al.] (Bentham Science Publishers Ltd, 2008)
Capecitabine is a drug that requires the consecutive action of three enzymes: carboxylesterase 2 (CES 2), cytidine deaminase (CDD), and thymidine phosphorylase (TP) for transformation into 5-fluorouracil (5FU). The ... -
A microRNA signature associated with early recurrence in breast cancer.
Pérez-Rivas, Luis G.; Jerez-Aragonés, José Manuel; Carmona, Rosario; De Luque, Vanessa; Vicioso-Recio, Luis Prudencio; Claros-Díaz, Manuel Gonzalo; Viguera-Mínguez, Enrique; Pajares, Bella; Sánchez-Muñoz, Alfonso; Ribelles, Nuria; Alba-Conejo, Emilio; Lozano-Castro, José[et al.] (PLOS, 2014-03-14)
Recurrent breast cancer occurring after the initial treatment is associated with poor outcome. A bimodal relapse pattern after surgery for primary tumor has been described with peaks of early and late recurrence occurring ... -
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study
Alba-Conejo, Emilio; Chacón, J. L.; Lluc, A.; Antón, A.; Estévez, L.; Cirauqui, B.; Carrasco, E.; Calvo, L.; Seguí, M.A.; Ribelles, Nuria; Álvarez, R.; Sánchez-Muñoz, Alfonso; Sánchez, R.; Lopez Garcia-Asenjo, J.A.; Rodriguez-Martin, C.; Escudero, M.J.; Albanell, J.[et al.] (Springer, 2012-10)
Abstract Chemotherapy remains as the only systemic treatment option available for basal-like breast cancer (BC) patients. Preclinical models and several phase II studies suggested that platinum salts are active drugs in ... -
Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma.
Oliver, Javier; Onieva Zafra, Juan Luis; Garrido-Barros, María; Berciano-Guerrero, Miguel Ángel; Sánchez-Muñoz, Alfonso; Lozano, María José; Farngren, Angela; Álvarez-Pérez, Martina; Martínez-Gálvez, Beatriz; Pérez-Ruiz, Elisabeth; Alba-Conejo, Emilio; Cobo Dols, Manuel Ángel; Rueda-Domínguez, Antonio; Barragán, Isabel[et al.] (MDPI, 2022)
Cutaneous melanoma (CM) is the most lethal form of skin cancer if it becomes metastatic, where treatment options and survival chances decrease dramatically. Immunotherapy treatments based on the immunologic checkpoint ... -
Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
Sánchez-Muñoz, Alfonso; Mendiola, César; Pérez-Ruiz, Elisabeth; Rodríguez-Sánchez, César A.; Jurado, José Miguel; Alonso-Carrión, Lorenzo Javier; Ghanem, Ismael; Velasco, Guillermo de; Quero-Blanco, Cristina; Alba-Conejo, Emilio[et al.] (KARGER, 2010-11)
Aim: To retrospectively assess the efficacy and safety of bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Patients and Methods: Patients with recurrent ... -
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
Godoy-Ortiz, Ana; Sánchez-Muñoz, Alfonso; Chica Parrado, María del Rosario; Álvarez-Pérez, Martína; Ribelles, Nuria; Rueda-Domínguez, Antonio; Alba-Conejo, Emilio[et al.] (Frontiers Media, 2019)
The main obstacle for designing effective treatment approaches in breast cancer is the extensive and the characteristic heterogeneity of this tumor. The vast majority of critical genomic changes occurs during breast cancer ... -
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Díaz-Redondo, Tamara; Lavado Valenzuela, Rocío; Jiménez-Rodríguez, Begoña; Pascual, Tomás; Gálvez, Fernando; Falcón, Alejandro; Álamo, María del Carmen; Morales-Estévez, Cristina; Amerigo, Marta; Pascual, Javier; Sánchez-Muñoz, Alfonso; González-Guerrero, Macarena; Vicioso-Recio, Luis Prudencio; Laborda-Illanes, Aurora; Ortega-Jiménez, María Victoria; Pérez-Villa, Lidia; Fernández-Martínez, Aranzazu; Chic, Nuria; Jerez-Aragonés, José Manuel; Álvarez-Pérez, Martína; Prat, Aleix; Ribelles, Nuria; Alba-Conejo, Emilio[et al.] (Frontiers Media, 2019)
Double blockade with pertuzumab and trastuzumab combined with chemotherapy is the standard neoadjuvant treatment for HER2-positive early breast cancer. Data derived from clinical trials indicates that the response rates ... -
High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade.
Onieva Zafra, Juan Luis; Xiao, Qingyang; Berciano-Guerrero, Miguel Ángel; Laborda-Illanes, Aurora; de Andrea, Carlos; Chaves, Patricia; Piñeiro Pereda, María del Pilar; Garrido-Aranda, Alicia; Gallego-Domínguez, Elena María; Sojo, Belén; Gálvez Carvajal, Laura; Chica Parrado, María del Rosario; Prieto Cuadra, Juan Daniel; Pérez-Ruiz, Elisabeth; Farngren, Angela; Lozano, María José; Álvarez-Pérez, Martína; Jiménez, Pedro; Sánchez-Muñoz, Alfonso; Oliver, Javier; Cobo Dols, Manuel Ángel; Alba-Conejo, Emilio; Barragán, Isabel[et al.] (MDPI, 2022)
Resistance to Immune Checkpoint Blockade (ICB) constitutes the current limiting factor for the optimal implementation of this novel therapy, which otherwise demonstrates durable responses with acceptable toxicity scores. ... -
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.
Sánchez-Muñoz, Alfonso; Gallego-Domínguez, Elena María; De Luque, Vanessa; Pérez-Rivas, Luis G.; Vicioso-Recio, Luis Prudencio; Ribelles, Nuria; Lozano-Castro, José; Alba-Conejo, Emilio[et al.] (Springer Nature, 2010-04-13)
Background: Mutational analysis of the KRAS gene has recently been established as a complementary in vitro diagnostic tool for the identification of patients with colorectal cancer who will not benefit from anti-epidermal ... -
Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HRþ)/HER2-negative advanced breast cancer patients.
Ribelles, Nuria; Jerez-Aragonés, José Manuel; Rodríguez-Brazzarola, Pablo; Jiménez-Rodríguez, Begoña; Díaz-Redondo, Tamara; Mesa, Héctor; Márquez, Antonia; Sánchez-Muñoz, Alfonso; Pajares, Bella; Carabantes, Francisco; Bermejo-Pérez, María José; Villar, Ester; Domínguez-Recio, María Emilia; Saez-Lara, Enrique; Gálvez Carvajal, Laura; Godoy-Ortiz, Ana; Franco, Leónardo; Ruiz-Medina, Sofía; López, Irene; Alba-Conejo, Emilio[et al.] (Elsevier, 2021)
Background: CDK4/6 inhibitors plus endocrine therapies are the current standard of care in the first-line treatment of HRþ/HER2-negative metastatic breast cancer, but there are no well-established clinical or molecular ... -
Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes
Sánchez-Muñoz, Alfonso; Vicioso-Recio, Luis Prudencio; Santonja, Angela; Alvaréz, Martina; Plata-Fernández, Yéssica; Miramón, José; Zarcos, Irene; Ramírez-Tortosa, César; Montes-Torres, Julio; Jerez-Aragonés, José Manuel; De Luque, Vanessa; Llácer, Casilda; Fernández-De Sousa, C.E.; Pérez-Villa, Lidia; Alba-Conejo, Emilio[et al.] (Elsevier, 2018-02)
Male breast cancer is a rare disease that is still poorly understood. It is mainly classified by immunohistochemistry as a luminal disease. In this study, we assess for the first time the correlation between molecular ... -
Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
Sánchez-Muñoz, Alfonso; Vicioso-Recio, Luis Prudencio; Santonja, Ángela; Álvarez-Pérez, Martína; Plata-Fernández, Yéssica; Miramón, José; Zarcos, Irene; Ramírez-Tortosa, C.L.; Montes-Torres, Julio; Jérez, J.M.; De Luque, Vanessa; Llácer, Casilda; Fernández-De Sousa, C.E.; Pérez-Villa, Lidia; Alba-Conejo, Emilio[et al.] (Elsevier, 2017-09-22)
Male breast cancer is a rare disease that is still poorly understood. It is mainly classified by immunohistochemistry as a luminal disease. In this study, we assess for the first time the correlation between molecular ... -
Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.
Ribelles, Nuria; Jerez-Aragonés, José Manuel; Pajares, Bella; Vicioso-Recio, Luis Prudencio; Jiménez-Rodríguez, Begoña; De Luque, Vanessa; Franco, Leónardo; Gallego-Domínguez, Elena María; Márquez, Antonia; Álvarez, Martina; Sánchez-Muñoz, Alfonso; Pérez-Rivas, Luis G.; Alba-Conejo, Emilio; Ribelles, Nuria[et al.] (BMC, 2013-10-22)
Recurrence risk in breast cancer varies throughout the follow-up time. We examined if these changes are related to the level of expression of the proliferation pathway and intrinsic subtypes. Results: Luminal A displayed ... -
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER1) node-negative breast cancer
Albanell, J.; González, A.; Ruiz-Borrego, M; Alba-Conejo, Emilio; García-Saenz, J.A.; Corominas, J. M.; Burgues, O.; Furio, V.; Rojo, A.; Palacios, J.; Bermejo, B.; Martínez-García, M.; Limón, L.M.; Sánchez-Muñoz, Alfonso; Martín, M.; Tusquets, I.; Rojo, R.; Colomer, R.; Faull, F.; Lluch, A.[et al.] (Elsevier, 2012-03)
This study examined the impact of the Recurrence Score (RS) in Spanish breast cancer patients and explored the associations between clinicopathological markers and likelihood of change in treatment recommendations. Patients ... -
Serum protein levels following surgery in breast cancer patients: A protein microarray approach
Pérez-Rivas, Luis G.; Jérez, J.M.; Fernández-De Sousa, C.E.; De Luque, Vanessa; Quero, C.; Pajares, Bella; Franco, L.; Sánchez-Muñoz, Alfonso; Ribelles, Nuria; Alba-Conejo, Emilio[et al.] (Spandidos Publications, 2012-07)
Surgery is the primary treatment for non-metastatic breast cancer. However, the risk of early recurrence remains after surgical removal of the primary tumor. Recurrence is suggested to result from hidden micrometastatic ... -
Targeted therapies in the treatment of germ cell tumors: The need for new approaches against “orphan” tumors
Sánchez-Muñoz, Alfonso; Jiménez-Rodríguez, Begoña; Navarro-Pérez, Víctor; Medina-Rodríguez, Laura; Llácer, Casilda; Vicioso-Recio, Luis Prudencio; Machuca, Javier; Alba-Conejo, Emilio[et al.] (Elsevier Ireland Ltd, 2012)
Germ cell tumors (GCTs) are a heterogeneous group of tumors that are highly clinically relevant to oncologists. GCTs are generally highly sensitive to cisplatin-based chemotherapy and represent a model for curable neoplasms. ... -
Targeted treatment approaches in refractory germ cell tumors
Gálvez Carvajal, Laura; Sánchez-Muñoz, Alfonso; Ribelles, Nuria; Saez, Maribel; Baena, Javier; Ruiz, Sofía; Ithurbisquy, Catherine; Alba-Conejo, Emilio[et al.] (Elsevier, 2019)
Germ cell tumors (GCTs) are the most common type of solid tumor amongst patients between 15 and 35 years of age. They are also one of the types of tumor with the highest cure rate, due to their high sensitivity to cisplatin ... -
Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy.
Santonja, Ángela; Sánchez-Muñoz, Alfonso; Lluch, Ana; Chica Parrado, María del Rosario; Albanell, J.; Chacón, José Ignacio; Antolín, Silvia; Jerez-Aragonés, José Manuel; De la Haba, Juan; De Luque, Vanessa; Fernández-De-Sousa, Cristina Elisabeth; Vicioso-Recio, Luis Prudencio; Plata-Fernández, Yéssica; Ramírez-Tortosa, César; Álvarez-Pérez, Martína; Llácer, Casilda; Zarcos-Pedrinaci, Irene; Carrasco, Eva; Caballero, Rosalía; Martín, Miguel; Alba-Conejo, Emilio[et al.] (Impact Journals, 2018-05-29)
Triple negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study is to explore the clinical ... -
Validity and reliability of the Spanish fear-avoidance components scale in breast cancer survivors
Gutiérrez-Sánchez, Daniel; Roldán-Jiménez, Cristina; Pajares, Bella; Alba-Conejo, Emilio; Cuesta-Vargas, Antonio (Wiley, 2021-08-23)
Objective:The aim of this study was to carry out a psychometric analysis of theFear-Avoidance Components Scale (FACS-Sp) in Spanish breast cancer survivors(BCS).Methods:A validation study was carried out in 154 BCS. ...